Recent CPIX News
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 04/28/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 09:08:24 PM
- Cumberland Pharmaceuticals jumps on $100M Apotex transaction • IH Market News • 04/23/2026 02:52:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 01:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 01:01:32 PM
- Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex • PR Newswire (US) • 04/23/2026 01:00:00 PM
- RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 • PR Newswire (US) • 04/22/2026 12:00:00 PM
- CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE • PR Newswire (US) • 04/16/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:24:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:22:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:21:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 09:20:05 PM
- Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting • PR Newswire (US) • 03/17/2026 01:05:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/12/2026 09:00:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/09/2026 09:03:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 09:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:28 PM
- CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® • PR Newswire (US) • 02/25/2026 12:00:00 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
- CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE • PR Newswire (US) • 02/24/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 10:20:03 PM
- Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program • PR Newswire (US) • 02/04/2026 02:05:00 PM
